Javascript must be enabled to continue!
Inhibition of NO‐synthase and degranulation of rat omental mast cells in vitro
View through CrossRef
Mast cell amines, platelet‐activating factor (PAF), thromboxanes and leukotrienes have been shown to be released during nitric oxide‐synthase inhibition in the rat intestine. Mast cells in rat isolated omentum (OMCs) or isolated from the rat peritoneal cavity (PMCs) have been used here to investigate the relationship(s) between these agents. N‐nitro‐L‐arginine methyl ester (L‐NAME, 100 μM) caused some degranulation of OMCs, but no enhancement of histamine release from PMCs. PAF (5 μM) and U46619 (1 μM) degranulated OMCs and enhanced histamine release from PMCs. Pre‐treatment of the omentum with BN52021 (10 μM) inhibited degranulation of OMCs in response to L‐NAME, PAF or U46619. Pretreatment with 1‐benzylimidazole (5 or 50 μM) inhibited the effect of L‐NAME but not that of PAF. Indomethacin (1 μM) or sodium nitroprusside (10 μM) also inhibited the effects of L‐NAME, but nordihydroguaiaretic acid (30 μM) did not. In PMCs BN52021 inhibited PAF‐induced, but not U46619‐induced, release of histamine. These results suggest that inhibition of nitric oxidesynthase in the omentum by L‐NAME allows thromboxanes to release PAF, which in turn degranulates and releases histamine from OMCs.
Title: Inhibition of NO‐synthase and degranulation of rat omental mast cells in vitro
Description:
Mast cell amines, platelet‐activating factor (PAF), thromboxanes and leukotrienes have been shown to be released during nitric oxide‐synthase inhibition in the rat intestine.
Mast cells in rat isolated omentum (OMCs) or isolated from the rat peritoneal cavity (PMCs) have been used here to investigate the relationship(s) between these agents.
N‐nitro‐L‐arginine methyl ester (L‐NAME, 100 μM) caused some degranulation of OMCs, but no enhancement of histamine release from PMCs.
PAF (5 μM) and U46619 (1 μM) degranulated OMCs and enhanced histamine release from PMCs.
Pre‐treatment of the omentum with BN52021 (10 μM) inhibited degranulation of OMCs in response to L‐NAME, PAF or U46619.
Pretreatment with 1‐benzylimidazole (5 or 50 μM) inhibited the effect of L‐NAME but not that of PAF.
Indomethacin (1 μM) or sodium nitroprusside (10 μM) also inhibited the effects of L‐NAME, but nordihydroguaiaretic acid (30 μM) did not.
In PMCs BN52021 inhibited PAF‐induced, but not U46619‐induced, release of histamine.
These results suggest that inhibition of nitric oxidesynthase in the omentum by L‐NAME allows thromboxanes to release PAF, which in turn degranulates and releases histamine from OMCs.
Related Results
Degranulation of rat omental mast cells by A1 receptor agonists in vitro
Degranulation of rat omental mast cells by A1 receptor agonists in vitro
The haemodynamic effects of adenosine are thought to result in part from a release of mast cell amines via A3 receptor stimulation. To investigate the nature of the receptors invol...
Abstract B089: Intratumoral expression analysis of mast cells in high grade serous ovarian cancer
Abstract B089: Intratumoral expression analysis of mast cells in high grade serous ovarian cancer
Abstract
Objective: The goal of this study is to examine intratumoral expression and phenotypic changes in mast cells following neoadjuvant chemotherapy (NACT) expos...
Clemastine Fumarate Attenuates Myocardial Ischemia Reperfusion Injury Through Inhibition of Mast Cell Degranulation
Clemastine Fumarate Attenuates Myocardial Ischemia Reperfusion Injury Through Inhibition of Mast Cell Degranulation
Mast cell (MC) activation is associated with myocardial ischemia reperfusion injury (MIRI). Suppression of MC degranulation might be a target of anti-MIRI. This study aimed to dete...
Human skin–derived mast cells can proliferate while retaining their characteristic functional and protease phenotypes
Human skin–derived mast cells can proliferate while retaining their characteristic functional and protease phenotypes
AbstractHuman mast cells in adult tissues have been thought to have limited, if any, proliferative potential. The current study examined mast cells obtained from adult skin and cul...
Mast cells in the kidney
Mast cells in the kidney
SUMMARY: Mast cells have become a recent concern in the nephrological world. The development of antibodies to mast cell‐specific enzymes, tryptase and chymase, has facilitated the ...
A Quantitative Analysis of Mast Cells in Inflammatory Periapical and Gingival Lesions
A Quantitative Analysis of Mast Cells in Inflammatory Periapical and Gingival Lesions
ABSTRACT
Aim
The aim of the study was to quantify the presence of mast cells in various inflammatory lesions like periapical granuloma, periapical cyst, inflammatory gingival hype...
GW24-e1023 Advanced Glycation End Product Modified Low Density Lipoprotein Activates Mast Cells via Toll-Like 4 Receptor Pathway
GW24-e1023 Advanced Glycation End Product Modified Low Density Lipoprotein Activates Mast Cells via Toll-Like 4 Receptor Pathway
Objectives
To investigate the effects of AGE-LDL, in murine bone marrow-derived mast cells (mBMMCs), on mast cell degranulation and their possible signal pathways...
PROCEEDINGS OF THE AUSTRALASIAN SOCIETY OF CLINICAL AND EXPERIMENTAL PHARMACOLOGISTS
PROCEEDINGS OF THE AUSTRALASIAN SOCIETY OF CLINICAL AND EXPERIMENTAL PHARMACOLOGISTS
1.Effect of chronic haloperidol treatment on D‐2 receptors labelled by (3H)‐spiperone in homogenates of rat corpus striatum. A. L. Gundlach, D. J. de Vries and P. M. Beart2.The eff...

